Merck's updated full-year earnings guidance is in the range of $3.31 to $3.39 a share, vs. the previously expected earnings of $3.29 to $3.39. The company expects full-year revenue of $45.4 billion to $46.1 billion.
Analysts, on average, expect 2010 earnings of $3.36 a share on revenue of $45.58 billion.
The company said full-year Medicaid rebates could reduce revenue by about $170 million.
Merck said third-quarter net income fell to 90% to $341.6 million, or 11 cents a share, from $3.42 billion, or $1.61, the previous year. The company said total costs associated with the company's global restructuring programs were $387 million in the third quarter vs. $117 million the year before. Merck also reported a negative impact of a $950 million legal reserve established in connection with a Vioxx drug investigation on by the U.S. Attorney's Office for the District of Massachusetts.
Non-GAAP EPS for the quarter was 85 cents vs. the consensus expectation of 82 cents. Sales rose 84% to $11.12 billion from $6.05 billion a year earlier. On average, analysts expected sales of $11.23 billion.
-- Written by Andrea Tse in New York.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
Copyright 2010 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.